Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 6/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.39 |
| ▸ | UBE2M | P61081 | 3/20 | 0.38 |
| ▸ | DCUN1D1 | Q96GG9 | 3/20 | 0.38 |
| ▸ | BDKRB1 | P46663 | 2/20 | 0.37 |
| ▸ | CCR2 | P41597 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31478948 | 1.00 | OPRK1 (0.43) | OPRK1CYP2D6HRH3OPRM1OPRD1 | |
| SCHEMBL9104308 | 0.86 | TACR2 (0.41) | OPRK1CYP2D6 | |
| SCHEMBL31478933 | 0.86 | TACR2 (0.41) | OPRK1CYP2D6 | |
| SCHEMBL9104300 | 0.86 | TACR2 (0.41) | OPRK1CYP2D6 | |
| SCHEMBL9104502 | 0.82 | HRH3 (0.44) | OPRK1CYP2D6HRH3OPRM1OPRD1 | |
| SCHEMBL9104486 | 0.82 | HRH3 (0.44) | OPRK1CYP2D6HRH3OPRM1OPRD1 | |
| SCHEMBL9106114 | 0.80 | SMO (0.41) | OPRK1CYP2D6OPRM1OPRD1 | |
| SCHEMBL9106105 | 0.80 | SMO (0.41) | OPRK1CYP2D6OPRM1OPRD1 | |
| SCHEMBL9102911 | 0.78 | HRH3 (0.44) | OPRK1CYP2D6HRH3OPRM1OPRD1 | |
| SCHEMBL9101346 | 0.78 | HRH3 (0.44) | OPRK1CYP2D6HRH3OPRM1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130143858-A1 | COMPOUNDS AND THEIR USE AS IKACH BLOCKERS | ASTRAZENECA AB (SE) | 2013-06-06 | — | — | US | disclosed |
| US-8361998-B2 | Compounds and their use as IKACh blockers | ASTRAZENECA AB | 2013-01-29 | — | — | US | disclosed |
| WO-2012074469-A1 | NEW IKACH BLOCKERS | ASTRAZENECA AB (SE) | 2012-06-07 | — | — | WO | disclosed |
| US-20120142659-A1 | COMPOUNDS AND THEIR USE AS IKACH BLOCKERS | ASTRAZENECA AB (SE) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130143858-A1 | COMPOUNDS AND THEIR USE AS IKACH BLOCKERS | KCNH2, KCNJ2, KCNH3 | OPRK1 398/4885CYP2D6 1483/4885HRH3 942/4885 |
| US-20120142659-A1 | COMPOUNDS AND THEIR USE AS IKACH BLOCKERS | KCNH2, KCNJ2, KCNH3 | OPRK1 398/4885CYP2D6 1483/4885HRH3 942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.